Tumour lysis syndrome: New therapeutic strategies and classification

British Journal of Haematology

Volumn 127, Issue 1, 2004, Pages 3-11

  Cairo, Mitchell S ^a   Bishop, Michael ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allopurinol; Rasburicase; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; AZATHIOPRINE; GLUCONATE CALCIUM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; INSULIN; MERCAPTOPURINE; RASBURICASE;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; BURKITT LYMPHOMA; CELL PROLIFERATION; CYTOTOXICITY; DISEASE CLASSIFICATION; DIURESIS; EARLY DIAGNOSIS; ELECTROLYTE BALANCE; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HOMEOSTASIS; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; INTRACELLULAR TRANSPORT; MALE; METABOLIC DISORDER; METABOLITE; NUCLEIC ACID ANALYSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; TUMOR LYSIS SYNDROME; UREMIA; URIC ACID BLOOD LEVEL;

ALLOPURINOL; HUMANS; TUMOR LYSIS SYNDROME; WATER-ELECTROLYTE IMBALANCE;

EID: 4944233187     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05094.x     Document Type: Review

References (42)

1. Andreoli, S.P., Clark, J.H., McGuire, W.A. & Bergstein, J.M. (1986) Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. The Journal of Pediatrics, 109, 292-298.
2. Band, P.R., Silverberg, D.S., Henderson, J.F., Ulan, R.A., Wensel, R.H., Banerjee, T.K. & Little, A.S. (1970) Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. The New England Journal of Medicine, 283, 354-357.
3. Bishop, M.R. & Coccia, P.F. (2000) Tumor lysis syndrome. In: Clinical Oncology (ed. by M.D. Abeloff, J.E. Niederhuber, J.O. Armitage & A.S. Lichter), pp. 750-754. Churchill Livingstone, New York.
4. Brogard, J.M., Coumaros, D., Franckhauser, J., Stahl, A. & Stahl, J. (1972) Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Revue Europeenne D Etudes Cliniques et Biologiques, 17, 890-895.
5. Cairo, M.S. (2003) Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome. Clinical Lymphoma, 3, 233-234.
6. Cohen, L.F., Balow, J.E., Magrath, I.T., Poplack, D.G. & Ziegler, J.L. (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. The American Journal of Medicine, 68, 486-491.
7. DeConti, R.C. & Calabresi, P. (1966) Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. The New England Journal of Medicine, 274, 481-486.
8. Frei, E.I., Bentzel, C.J., Rieselbach, R. & Block, J.B. (1963) Renal complications of neoplastic disease. Journal of Chronic Diseases, 16, 757-776.
9. Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. & Cairo, M.S. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
10. Hande, K.R. & Garrow, G.C. (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. The American Journal of Medicine, 94, 133-139.
11. Hande, K.R., Hixson, C.V. & Chabner, B.A. (1981) Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Research, 41, 2273-2279.
12. Heney, D., Essex-Cater, A., Brocklebank, J.T., Bailey, C.C. & Lewis, L.J. (1990) Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatric Nephrology, 4, 245-247.
13. Jeha, S. (2001) Tumor lysis syndrome. Seminars in Hematology, 38, 4-8.
14. Jones, D.P., Mahmoud, H. & Chesney, R.W. (1995) Tumor lysis syndrome: pathogenesis and management. Pediatric Nephrology, 9, 206-212.
15. Kedar, A., Grow, W. & Neiberger, R.E. (1995) Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatric Hematology and Oncology, 12, 129-134.
16. Kelly, K.M. & Lange, B. (1997) Oncologic emergencies. Pediatric Clinics of North America, 44, 809-830.
17. Klinenberg, J.R., Goldfinger, S. & Seegmiller, J.E. (1965) The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Annals of Internal Medicine, 62, 638.
18. Krakoff, I.H. & Meyer, R.L. (1965) Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. Journal of the American Medical Association, 193, 89-94.
19. Landgrebe, A.R., Nyhan, W.L. & Coleman, M. (1975) Urinary-tract stones resulting from the excretion of oxypurinol. The New England Journal of Medicine, 292, 626-627.
20. Legoux, R., Delpech, B., Dumont, X., Guillemot, J.C., Ramond, P., Shire, D., Caput, D., Ferrara, P. & Loison, G. (1992) Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase. The Journal of Biological Chemistry, 267, 8565-8570.
21. Masera, G., Jankovic, M., Zurlo, M.G., Locasciulli, A., Rossi, M.R., Uderzo, C. & Recchia, M. (1982) Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. The Journal of Pediatrics, 100, 152-155.
22. O'Regan, S., Carson, S., Chesney, R.W. & Drummond, K.N. (1977) Electrolyte and acid-base disturbances in the management of leukemia. Blood, 49, 345-353.
23. Patte, C., Sakiroglu, C., Ansoborlo, S., Baruchel, A., Plouvier, E., Pacquement, H. & Babin-Boilletot, A. (2002) Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Annals of Oncology, 13, 789-795.
24. Pui, C.H. (2002) Rasburicase: a potent uricolytic agent. Expert Opinion on Pharmacotherapy, 3, 433-442.
25. Pui, C.H., Relling, M.V., Lascombes, F., Harrison, P.L., Struxiano, A., Mondesir, J.M., Ribeiro, R.C., Sandlund, J.T., Rivera, G.K., Evans, W.E. & Mahmoud, H.H. (1997) Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 11, 1813-1816.
26. Pui, C.H., Mahmoud, H.H., Wiley, J.M., Woods, G.M., Leverger, G., Camitta, B., Hastings, C., Blaney, S.M., Relling, M.V. & Reaman, G.H. (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. The Journal of Clinical Oncology, 19, 697-704.
27. Razis, E., Arlin, Z.A., Ahmed, T., Feldman, E.J., Puccio, C., Cook, P., Chun, H.G., Helson, L. & Mittelman, A. (1994) Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematologica, 91, 171-174.
28. Ribeiro, R.C. & Pui, C.H. (2003) Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clinical Lymphoma, 3, 225-232.
29. Sakarcan, A. & Quigley, R. (1994) Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatric Nephrology, 8, 351-353.
30. Seegmiller, J.E., Laster, L. & Howell, R.R. (1963) Biochemistry of uric acid and its relationship to gout. The New England Journal of Medicine, 268, 712-716.
31. Silverman, P. & Distelhorst, C.W. (1989) Metabolic emergencies in clinical oncology. Seminars in Oncology, 16, 504-515.
32. Smalley, R.V., Guaspari, A., Haase-Statz, S., Anderson, S.A., Cederberg, D. & Hohneker, J.A. (2000) Allopurinol: intravenous use for prevention and treatment of hyperuricemia [published erratum appears in J Clin Oncol 2000 May;18(10):2188]. Journal of Clinical Oncology, 18, 1758-1763.
33. Smalley, R.V., Guaspari, A., Haase-Statz, S., Anderson, S.A., Cederberg, D. & Hohneker, J.A. (2000) Allopurinol: intravenous use for prevention and treatment of hyperuricemia [published erratum appears in J Clin Oncol 2000 May;18(10):2188]. Journal of Clinical Oncology, 18, 1758-1763.
34. Spector, T. (1977) Inhibition of urate production by allopurinol. Biochemical Pharmacology, 26, 355-358.
35. Tannock, I. (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treatment Reports, 62, 1117-1133.
36. Ten Harkel, A.D., Kist-Van Holthe, J.E., Van Weel, M. & Van der Vorst, M.M. (1998) Alkalinization and the tumor lysis syndrome. Medical and Pediatric Oncology, 31, 27-28.
37. Tsokos, G.C., Balow, J.E., Spiegel, R.J. & Magrath, I.T. (1981) Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine, 60, 218-229.
38. Vachvanichsanong, P., Maipang, M., Dissaneewate, P., Wongchanchailert, M. & Laosombat, V. (1995) Severe hyperphosphatemia following acute tumor lysis syndrome. Medical and Pediatric Oncology, 24, 63-66.
39. Van den Berghe, G. (2000) Purine and pyrimidine metabolism between millennia: what has been accomplished, what has to be done? Advances in Experimental Medicine and Biology, 486, 1-4.
40. Wechsler, D.S., Kastan, M.B. & Fivush, B.A. (1994) Resolution of nephrocalcinosis associated with tumor lysis syndrome. Pediatric Hematology and Oncology, 11, 115-118.
41. Yeldandi, A.V., Yeldandi, V., Kumar, S., Murthy, C.V., Wang, X.D., Alvares, K., Rao, M.S. & Reddy, J.K. (1991) Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene, 109, 281-284.
42. Zusman, J., Brown, D.M. & Nesbit, M.E. (1973) Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. The New England Journal of Medicine, 289, 1335-1340.